In a case that closed as swiftly as it began, American Regent, Inc. voluntarily dismissed — without prejudice — all patent infringement claims against Apotex, Inc. and Apotex Corp. in the Delaware District Court (Case No. 1:24-cv-00327), just 128 days after filing on March 13, 2024. The asserted patent, U.S. Patent No. US11786548B2, covers formulations related to trace elements injection 4* (USP), the active pharmaceutical ingredient class underpinning American Regent’s branded product Tralement® and implicated by Apotex’s generic equivalent. The case was presided over by Chief Judge Stephanos Bibas and terminated on July 19, 2024, via Fed. R. Civ. P. 41(a)(1)(A)(i) dismissal.

For IP strategists and pharmaceutical patent litigators, this dismissal — filed without any recorded defendant appearance or answer — carries significant strategic weight. Voluntary dismissals without prejudice in ANDA-adjacent pharmaceutical litigation often signal ongoing licensing negotiations, regulatory timing adjustments, or a plaintiff’s recalibrated litigation posture. Understanding why American Regent stepped back, and what it means for the competitive landscape surrounding trace elements injectable formulations, is critical for counsel monitoring generic entry risk in this space.

Case Overview

The Parties

The Patent at Issue

U.S. Patent No. US11786548B2 (Application No. US17/365695) covers formulations and methods related to trace elements injection 4*, USP — a sterile intravenous solution combining essential micronutrients including zinc, copper, manganese, and selenium, used in parenteral nutrition for critically ill patients. The patent’s claims likely encompass specific concentration ranges, formulation stability characteristics, and manufacturing processes that differentiate branded Tralement® and Multrys® from compounded or generic alternatives. These formulations are used in hospital settings where precision dosing of trace elements is critical to patient safety and clinical outcomes.

• • US11786548B2

Legal Representation

Plaintiff Counsel: Gibbons PC (lead: Christopher Viceconte)

Litigation Timeline & Procedural History

The case was filed on March 13, 2024, in the District of Delaware — the preeminent venue for pharmaceutical patent litigation in the United States, particularly for Hatch-Waxman and ANDA-related disputes, where courts and practitioners have deep familiarity with the statutory 30-month stay framework and associated procedural conventions. Filing in Delaware signals that American Regent anticipated a complex, high-stakes pharmaceutical IP dispute and sought a jurisdiction with predictable case management and established precedent on claim construction for formulation patents.

The case lasted only 128 days and closed on July 19, 2024, without any docketed defendant appearance, answer, or motion practice on record. American Regent exercised its right under Federal Rule of Civil Procedure 41(a)(1)(A)(i) — which permits a plaintiff to voluntarily dismiss an action without court order before the defendant serves an answer or motion for summary judgment — making the dismissal self-executing and requiring no judicial approval. This procedural mechanism, combined with the dismissal being without prejudice, preserves American Regent’s full right to re-file the same claims against Apotex at a later date, suggesting this closure reflects strategic repositioning rather than a concession on the merits.

The Verdict & Legal Analysis

Outcome

The case was terminated on July 19, 2024, via voluntary dismissal without prejudice pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i), initiated solely by plaintiff American Regent, Inc. No damages were awarded, no injunctive relief was granted, and no merits determination was made regarding infringement or validity of US11786548B2. Because the dismissal was without prejudice, American Regent retains the right to re-file infringement claims against Apotex based on the same patent and products.

Verdict Cause Analysis

The infringement action’s termination by voluntary dismissal — before any defendant response — reflects several legally significant procedural and strategic realities:

• American Regent filed the dismissal under Rule 41(a)(1)(A)(i), which is only available before the defendant serves an answer or a motion for summary judgment, indicating Apotex had not yet formally responded to the complaint at the time of dismissal.
• The without-prejudice designation means US11786548B2 remains fully enforceable and no claim or defense preclusion doctrine (such as res judicata) attaches to this termination, preserving American Regent’s litigation options.
• In Hatch-Waxman pharmaceutical litigation, voluntary early dismissals frequently accompany confidential licensing or settlement discussions, the expiration or modification of a 30-month regulatory stay, or a plaintiff’s decision to refile in a different venue or after claim amendments.
• No defendant law firm or agent was recorded in the case data, suggesting Apotex may not have formally appeared in the litigation before dismissal, which is consistent with very early-stage resolution or pre-answer negotiation.

Legal Significance

1. 1. Because the dismissal is without prejudice, this case establishes no claim construction record, no invalidity findings, and no infringement rulings — US11786548B2 retains its full presumption of validity and can be asserted again against Apotex or any other generic filer in future litigation.
2. 2. The speed of dismissal (128 days, before defendant answer) in a Delaware pharmaceutical patent case is consistent with industry patterns where ANDA paragraph IV litigation is settled or paused during negotiations over authorized generic agreements, licensing terms, or agreed entry dates, none of which would appear in the public record.
3. 3. For other generic manufacturers monitoring the trace elements injection 4* USP space, this dismissal does not create any safe harbor — American Regent’s patent US11786548B2 remains an active enforcement risk and the Multrys®/Tralement® product family retains its patent protection posture.

Strategic Takeaways

For Patent Attorneys:

• When representing pharmaceutical patentees in Hatch-Waxman litigation, structure any early settlement or licensing discussions to occur before the defendant’s answer deadline to preserve Rule 41(a)(1)(A)(i) as a clean exit mechanism if the case needs to be dismissed without prejudice.
• Counsel for generic defendants should be aware that an early voluntary dismissal without prejudice — as seen here — carries no preclusive effect; monitor the patent’s status and ANDA docket for re-filing risk and advise clients accordingly.
• In drafting ANDA paragraph IV certification opinions, the dismissal of American Regent v. Apotex should be noted but not relied upon as evidence of non-infringement or invalidity of US11786548B2, given the complete absence of merits adjudication.
• Consider filing a Rule 11-compliant declaratory judgment action for non-infringement or invalidity of US11786548B2 if Apotex or similarly situated generic filers wish to obtain affirmative certainty rather than awaiting a potential re-filing by American Regent.

For IP Professionals:

• In-house IP teams at generic pharmaceutical companies should flag US11786548B2 as an unresolved enforcement risk and track American Regent’s ANDA-related litigation activity across all relevant dockets, as a re-filing against Apotex or other paragraph IV filers remains legally permissible.
• Portfolio managers at branded pharmaceutical companies can use this case as a model for preserving optionality — a without-prejudice dismissal early in litigation can reset negotiating posture while keeping patent enforcement rights fully intact for future assertion.

For R&D Teams:

• R&D and regulatory teams at companies developing trace elements injection 4* USP products or parenteral nutrition formulations should conduct a thorough freedom-to-operate analysis against US11786548B2 before progressing ANDA or 505(b)(2) filings, as the patent’s enforceability is unaffected by this dismissal.
• Product development teams working on alternative trace element formulations — including different concentration profiles, stabilizers, or container configurations — should document design-around rationale contemporaneously to support both FTO positions and potential IPR petitions if litigation risk materializes.